Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Innovation in Community Oncology: Moving Faster, Close to Home
The 2026 Community Oncology Alliance conference highlighted how community practices are rapidly integrating advanced therapies such as CAR‑T and bispecific antibodies, supported by AI-driven workflow tools and new real‑world data standards. Speakers emphasized the need for expanded infusion capacity, symptom monitoring, and payer alignment to safely deliver these treatments outside academic centers. Flatiron Health’s VALID Framework and Paradigm Health’s acquisition of Flatiron’s research arm illustrate a growing ecosystem that links AI, real‑world evidence, and regulatory modernization. Advocacy remains critical to protect reimbursement and reduce administrative barriers.
Malaysia OKs Korean AI for Sepsis Prediction and More AI Briefs
South Korean AI firm AITRICS secured Class C medical‑device approval in Malaysia for its VitalCare sepsis‑prediction software, marking its sixth regulatory clearance after Indonesia. In Thailand, Taiwan’s Acer Medical teamed with local partners to deploy an integrated AI‑assisted eye‑screening and...
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
Propanc Biopharma announced a corporate update highlighting a service agreement with Germany’s FyoniBio to validate a pharmacokinetics assay for its lead asset PRP ahead of a Phase 1b first‑in‑human trial in solid‑tumor cancer patients. The company also secured a multi‑year anti‑aging...
New York State Announces Efforts to Bolster Maternal Mental Wellbeing
New York State’s Office of Mental Health announced over $18.4 million to expand the HealthySteps program, adding 38 new sites and boosting capacity by roughly 25%. In 2025 HealthySteps screened more than 108,000 new mothers for perinatal depression, part of a...
Protara Therapeutics Reports P-II (ADVANCED-2) Trial on TARA-002 in BCG-Naïve Non-Muscle Invasive Bladder Cancer (NMIBC)
Protara Therapeutics presented 12‑month data from Cohort A of its Phase II ADVANCED‑2 trial evaluating TARA‑002 in patients with carcinoma in situ or CIS‑plus‑Ta/T1 non‑muscle‑invasive bladder cancer (NMIBC) who are BCG‑naïve. Of the 31 enrolled, 29 were efficacy‑evaluable, yielding an overall...
GLP1 Access for Only a $50 Copay?
Medicare has unveiled a GLP‑1 Bridge program that begins on July 1, 2024 and runs through December 31, 2027. The initiative offers a flat $50 copayment for all four dosage tiers of GLP‑1 medicines, covering both injectable formulations and the new oral...
At Axios Future Of Health, The Real Story Was Infrastructure Debt
At the Axios Future of Health Summit, speakers exposed a deep‑seated infrastructure debt in U.S. healthcare. CMS Administrator Mehmet Oz announced an expanded “Axe the Fax” effort with leading health systems and EHR vendors to curb the reliance on fax...
CAR-T Therapy for Stiff Person Syndrome Nears Approval
Kyverna Therapeutics is close to securing regulatory approval for its CAR‑T cell therapy aimed at treating stiff person syndrome (SPS), a rare autoimmune neurological disorder with no approved drugs. The therapy uses engineered T cells to eliminate the B‑cell populations...
More GLP-1 Options Are Coming for Federal Retirees, but They Come with a Catch
The Centers for Medicare & Medicaid Services is launching the Medicare GLP‑1 Bridge program on July 1, extending coverage of select weight‑loss GLP‑1 drugs to eligible Part D beneficiaries regardless of medical condition. Federal retirees with FEHB‑linked Part D plans can now request...
AI Is Fabricating Citations in Biomedical Studies, Researchers Find
An audit of millions of biomedical papers uncovered more than 4,000 citations to non‑existent research, spanning nearly 3,000 articles. The incidence of fabricated references has surged twelvefold over the past three years, and none of the identified errors have been...
Resurge Therapeutics Presents Clinical Results on Its Intraprostatic Drug Elution (IPDE) Platform for Benign Prostatic Hyperplasia (BPH) at AUA 2026
Resurge Therapeutics presented data from two early‑phase studies of its intraprostatic drug elution (IPDE) platform for benign prostatic hyperplasia (BPH) at the AUA 2026 meeting. In the transperineal cohort of 20 patients, IPSS dropped 15 points and peak urinary flow...
UK Government Launches £473 Million Call for Evidence on New Mental Health Strategy
The UK government today launched a nationwide Call for Evidence to shape a once‑in‑a‑generation mental health strategy for England, backed by £473 million (≈ $600 m) of new funding. The plan aims to move services away from crisis‑led care toward early intervention, with...
Insurers Push Rural Patients Into Unsafe Off‑Site Chemo
A private insurer just decided that a cancer patient could not have her chemotherapy in the cancer center. She walked away from treatment entirely. This is the rollout most clinicians have not noticed yet, and it is starting in rural...
Brazilian Hospital Secures $6.3 M to Launch Global Child Depression Prevention Project
Hospital Moinhos de Vento in Porto Alegre has secured £5 million (≈$6.3 million) from the Wellcome Trust to spearhead the Idea‑Impact project, an international effort to prevent depression in children and teenagers before symptoms appear. The study will adapt Brazil’s Idea‑RS risk...
The Tragic Reality of Pregnancy-Associated Breast Cancer
Pregnancy‑associated breast cancer (PABC) affects roughly one in 3,000 pregnancies and is often a highly aggressive triple‑negative disease. The case of a 30‑year‑old mother who chose to keep her twins illustrates the clinical dilemma of balancing fetal safety with timely...
#ASGCT26: A Zillow-Like Marketplace for Abandoned Gene Therapies Goes Live
Two nonprofit groups, the American Society of Gene & Cell Therapy and the Orphan Therapeutics Accelerator, unveiled a Zillow‑style online marketplace that lists abandoned cell and gene therapy assets. The platform, launched at the ASGCT26 conference, aggregates more than 30...
Arna Pharma and Slate Run Complete JV for New US Company
Arna Pharma and Slate Run Pharmaceuticals have completed a joint venture to create a U.S.-based specialty pharmaceutical company focused on branded products, 505(b)(2) medicines, and specialized generics. The partnership launched its first collaborative product, Aridol, and plans to add more...
NICE Backs Stomach Cancer, PAH Drugs for NHS Use
The UK’s health technology assessment body NICE has endorsed AstraZeneca’s immunotherapy Imfinzi for peri‑operative treatment of aggressive stomach and gastro‑oesophageal junction cancers, and approved Merck & Co.’s Winrevair as an add‑on therapy for pulmonary arterial hypertension (PAH). More than 1,500 patients in...
Georgia Hospitals Deploy QR‑Code Bracelets to Flag Maternal Risk
Wellstar Health System and Piedmont Augusta have begun using QR‑code birth‑alert bracelets that let clinicians instantly view a patient’s medical history, a step aimed at reducing Georgia’s 30‑per‑100,000 maternal death rate. The initiative responds to state‑wide concerns about preventable pregnancy‑related...
Supreme Court Keeps Mail‑Order Access to Abortion Pill Mifepristone in Place
The U.S. Supreme Court voted to preserve mail‑order access to the abortion medication mifepristone, rejecting a lower‑court order that would have forced in‑person dispensing. The decision leaves the FDA’s 2023 policy intact as Louisiana’s lawsuit against the agency continues.
CAR T-Cell Therapy Bolstered by Stiffening up Cancer Cells First
Researchers have discovered that pre‑treating cancer cells to increase their stiffness markedly improves the effectiveness of CAR T‑cell therapy in mouse models of aggressive melanoma. The physical alteration of tumor mechanics enhances immune cell infiltration and tumor killing, offering a novel...
Women’s Health Investment: Rhetoric Vs. Reality
In a Pharmaceutical Executive interview, Toragen CEO Sandra Coufal argues that despite rising investor interest, funding for women‑specific treatments remains limited because total addressable market calculations rely on male‑biased trial data. This systemic under‑representation causes the commercial potential of women’s...
New Health Secretary Appointed – Will It Be Business as Usual?
James Murray, the former Chief Secretary to the Treasury, has been appointed Secretary of State for Health and Social Care. His tenure at the Treasury gives him intimate knowledge of the Department of Health and Social Care's budgets and reform...
Re: Hospital at Home Has Expanded Rapidly on the Assumption It’s What Patients Want—But What Do They Really Think?
A GP wrote to BMJ criticizing the rapid rollout of Hospital at Home, arguing the model may not reflect patient preferences. She cites Ian Watson, a terminal patient with vascular dementia, who received IV antibiotics at home and subsequently developed...
Bethany Dean | Meet the Speakers: Med-Tech Expo 2026
Bethany Dean, a senior advisor at Taylored Consultancy, will present at Med‑Tech Expo 2026 on how companies can navigate products that sit between medical device, cosmetic, medicinal, and general‑product definitions. Her session promises practical methods to identify borderline classifications, real‑world...
Minnesota Lawmaker Proposes Using Hospital Tax To Fill Charity Care Gap
Minnesota Rep. Steve Elkins introduced legislation to redirect the state’s 1.56% hospital tax revenue—about $250 million annually—back to hospitals to boost charity care, arguing it roughly equals the $241 million spent on such care in 2024. The move follows a Star Tribune‑KFF...
Massive Bio and Just Worldwide to Expand Cancer Trial Access
Massive Bio announced a strategic partnership with Just Worldwide to broaden access to oncology clinical trials. The deal combines Just Worldwide’s multicultural patient‑engagement infrastructure with Massive Bio’s SYNERGY‑AI matching engine, allowing patients to be onboarded, have records collected, and be...
Kyowa Kirin Secures FDA Approval for Crysvita Dosing Update
Kyowa Kirin has secured FDA approval to expand Crysvita’s dosing regimen for adults with X‑linked hypophosphataemia (XLH). The update allows a 0.5 mg/kg dose up to 90 mg every two weeks, with the option to increase to 1 mg/kg after four weeks if serum...
Kyowa Kirin Secures FDA Approval for Crysvita Dosing Update
Kyowa Kirin has secured FDA approval for a dosing update to Crysvita (burosumab‑twza) for adults with X‑linked hypophosphataemia (XLH). The new regimen permits a 0.5 mg/kg dose every two weeks, with the option to increase to 1 mg/kg after four weeks if serum...
Up to £20 Million National Funding for Referrals and Appointments Opens
NHS England has opened a national funding round of up to £20 million (≈$25 million) for 2026/27 to boost the Booking and Referral Standard, e‑Referral Service and NHS App. The money can be used to scale PIFU pathways, AI‑driven notifications, messaging and...
InterSystems Connects Medicus GP Systems Within West Midlands Shared Care Record
InterSystems UKI has integrated the Medicus GP platform into the West Midlands Shared Care Record, marking the first large‑scale deployment of a next‑generation primary‑care system within an NHS Integrated Care System. The rollout follows Doctolib’s £100 million (~$127 million) investment to accelerate...
Biogen Reports P-II (CELIA) Trial Results on Diranersen in Early Alzheimer’s Disease
Biogen disclosed phase‑II (CELIA) results for intrathecal diranersen in 416 patients with early Alzheimer’s disease. The trial did not meet its primary dose‑response endpoint on CDR‑SB at week 76, but all dosing arms, especially 60 mg every‑four‑weeks, showed a slowing of clinical...
SCOTUS Preserved Abortion by Mail. Opponents Already Know Their Next Moves.
The U.S. Supreme Court issued an emergency order restoring mail‑order access to mifepristone after the 5th Circuit temporarily blocked it, keeping telehealth abortions available while litigation continues. Providers like Dr. Angel Foster quickly adapted, using higher doses of misoprostol alone...
AstraZeneca’s Fasenra Receives the US FDA Approval for Hypereosinophilic Syndrome
The U.S. FDA has granted approval for AstraZeneca’s biologic Fasenra (benralizumab) to treat patients aged 12 and older with hypereosinophilic syndrome (HES) lacking a non‑hematologic secondary cause. Approval follows the Phase III NATRON trial, which enrolled 133 patients and compared 30 mg...
TANIOBIS Enables Patient-Specific Implants With Tantalum and Niobium Alloys
German materials firm TANIOBIS has expanded its AMtrinsic powder line to include tantalum‑niobium alloys, positioning them as a biocompatible alternative to the titanium‑6Al‑4V alloy that dominates orthopedic and dental implants. The new powders are optimized for laser‑based additive manufacturing, enabling...
As New Rules Take Hold, What Does ‘Good AI Practice’ Look Like in Drug Development?
On January 14 2026 the EMA and FDA published joint guiding principles that define good AI practice for drug development. The technology‑neutral framework emphasizes context of use, risk‑based controls, data governance, documentation and lifecycle management rather than adding new regulatory requirements. It...
Home Sensor Technology in Social Care Reform: Moving From Potential to Practice at Scale in Tech-Enabled Care
A NIHR‑commissioned rapid evaluation by the DECIDE centre examined home‑sensor pathways in adult social care across three local authorities. The study found that sensors can flag early health deterioration and reduce unnecessary visits, but privacy worries and anxiety limit uptake...
American College of Radiology Urges FDA to Address Breast Biopsy Needle Shortages
The American College of Radiology (ACR) has warned the FDA about a nationwide shortage of stereotactic breast biopsy needles that could last through 2026. The shortage began after a major manufacturer halted shipments following a safety notice on Hologic’s disposable...
Radiologist Must Pay $14,000 Fine, Undergo Training After Allegedly Overlooking Abnormalities on Brain Scan
Florida radiologist John S. Scales, MD, agreed to pay more than $14,000 and complete mandated training after the state Board of Medicine found he missed critical abnormalities on a 2019 head CT. The board issued a Letter of Concern, a...
How Big Health Brands Are Funding Online Medical Misinformation
A JAMA Network Open study by Yale researchers found that health‑related advertisers poured $35.7 million into 11 news sites flagged by NewsGuard for spreading false health information between 2021 and 2024. Overall ad spend on those sites reached $336 million, with major...
The Real Purpose of Succession Planning in Healthcare Facilities
In this episode, host Peter Martin talks with Paul DeViller, Director of Plant Operations at Lahey Medical Center, and Ryan Gagnon, Assistant Director of Plant Operations, about the real purpose of succession planning in healthcare facilities. They emphasize that succession...
Glooko Secures FDA 510(k) Clearance for First Cloud‑Based Inpatient Insulin Dosing Platform
Glooko announced that the FDA cleared its EndoTool IV Cloud through the 510(k) pathway, making it the first cloud‑based, patient‑specific insulin dosing platform for hospitals. The clearance paves the way for a commercial rollout in the United States before the...
GHX Launches AI‑Powered Orchestration Platform to Cut Healthcare Supply‑Chain Workflow Debt
Global Healthcare Exchange (GHX) introduced an AI‑driven orchestration layer at its New Orleans summit, promising to slash manual “workflow debt” across the provider‑supplier ecosystem. The platform, already used by more than 600 providers, leverages connected intelligence to sense disruption, decide...
CMS Tightens Hospital Price‑Transparency Enforcement, Issuing Record Fines
The Centers for Medicare & Medicaid Services began enforcing its toughest hospital price‑transparency rules in April, requiring CEOs to attest to accurate pricing and levying 10 civil penalties in 2025. The move targets placeholder pricing, expands data requirements, and creates...
Racura Oncology Advances CPACS Trial to Next Dose Level
Racura Oncology (ASX:RAC) received Safety Review Committee clearance to double the RC220 dose from 40 mg/m² to 80 mg/m² for Cohort 2 of its CPAPS Phase 1 trial, pairing the drug with doxorubicin. The first three Cohort 1 patients showed no dose‑limiting toxicities, and all...
The Key Ingredients of a Successful Radiologist-Wellness Initiative
A wellness program for community radiologists at Mass General Brigham Imaging combined brief group fitness sessions, family‑oriented social events, and financial‑wellness lectures. More than two‑thirds of the targeted radiologists joined, and a six‑month survey showed 84% felt social events boosted...
Viagra Shows Promise as Potential Treatment to Halt Peyronie’s Disease
A Phase‑II trial of 133 men with acute Peyronie’s disease tested an off‑label combination of a PDE5 inhibitor (sildenafil or tadalafil) and the SERM tamoxifen. After three months, 43% of participants reported a meaningful reduction in penile curvature versus 15%...
Biogen Seals $5.3 B Deal for Apellis, Adds Two Blockbuster Drugs
Biogen closed a $5.3 billion cash acquisition of Apellis Pharmaceuticals on May 14, 2026, bringing the complement‑driven therapies EMPAVELI and SYFOVRE into its portfolio. The transaction was financed with a new $2 billion unsecured term loan and includes a contingent value right...
RNA‑ROS Nanoplatform Cuts Skin Inflammation in Preclinical Tests
Researchers led by Cui, Lu and Cai unveiled a multifunctional nanoplatform that simultaneously delivers double‑stranded RNA and scavenges reactive oxygen species, achieving marked reductions in TNF‑α, IL‑6 and IL‑1β in skin inflammation models. The study, published in Nature Communications, signals...
FDA Approves First All‑Oral Decitabine/Cedazuridine + Venetoclax Regimen for Older AML Patients
Taiho Oncology announced that the U.S. FDA has approved Inqovi (decitabine/cedazuridine) combined with venetoclax for newly diagnosed acute myeloid leukemia patients aged 75 or older, or those unsuitable for intensive induction chemotherapy. The approval, based on a Phase 2 trial showing...